(MedPage Today) — News about Alzheimer’s rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers reported 3-year outcomes for both anti-amyloid drugs, lecanemab (Leqembi) and donanemab (Kisunla).
The…
Source link : https://www.medpagetoday.com/neurology/alzheimersdisease/118639
Author :
Publish date : 2025-11-21 14:07:00
Copyright for syndicated content belongs to the linked Source.
